

## IVACAFTOR SPECIAL AUTHORIZATION REQUEST FORM

Please complete all required sections to allow your request to be processed.

Patients may or may not meet eligibility requirements as established by Alberta Government sponsored drug programs.

PATIENT INFORMATION								COVERAGE TYPE			
PATIENT LAST NAME	FIRST NAME				INITIAL			☐ Alberta Blue Cross			
									Alberta Human Services		
BIRTH DATE (YYYY-MM-DD)	ALBE	ALBERTA PERSONAL HEALTH NUMBER						Other			
STREET ADDRESS	CITY			PF	ROV	POS	TAL CODE	ID/CLIE	ENT/COVERAGE NUM	MBER.	
PRESCRIBER INFORMATION											
PRESCRIBER LAST NAME FIRST NAME INITIAL					PRESC	RIBEF			SOCIATION REGISTI	RATION	
					☐ CPSA ☐ ACO REGISTRATION NUMBER☐ CARNA ☐ ADA+C						
STREET ADDRESS					ACP Other						
						PHONE			FAX		
CITY, PROVINCE											
DOOTAL CODE											
POSTAL CODE					FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED						
☐ NEW Please provide the following information for NEW requests											
Diagnosis											
Cystic Fibrosis											
Other (please specify)											
Mutation affecting the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene											
G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R											
□ R117H											
Other (please specify)											
Please provide the following <u>pre-treatment</u> information for NEW requests											
Sweat Chloride test (mmol/L)						Date					
, ,											
FEV <sub>1</sub> (pre-bronchodilator % predicted)					!			Date	Date		
☐ RENEWAL Please provide the following <u>current</u> information for RENEWAL requests											
Initial renewal					Subsequent renewals						
Sweat Chloride test (mmol/L)	(mmol/L)		Date		Sweat Chloride test (n			nmol/L)		Date	
FEV <sub>1</sub> (pre-bronchodilator % predicted) one			Date			FEV₁ (pre-bronchodila			erodictod)	Date	
month after starting treatment			Date			revi (pre-bronchodila			nedicted)	Date	
			Date								
months after starting treatment			Date								
Note: If the expected reduction in swe	at chlorid	a does	not or	CUI	the na	tient'	s CE clinic	ian will	first evolore any n	roblems in	
following the recommended dosing so											
later and funding discontinued if the p											
Additional information relating to re	equest										
PRESCRIBER'S SIGNATURE DATE						ard this request to					
					rta Blue Cross, Clinical Drug Services						
					108 Street NW, Edmonton, Alberta T5J 3C5 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas						
ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST											

The information on this form is being collected and pursuant to sections 20, 21 and 22 of the Health Information Act, and sections 33 and 34 of the Freedom of Information and Protection of Privacy Act, for the purposes of determining or verifying eligibility to participate in a program or receive a benefit, product or health service. If you have any questions regarding the collection or use of this information, please contact an Alberta Blue Cross privacy matters representative toll-free at 1-855-498-7302 or write to Privacy Matters, Alberta Blue Cross, 10009 108 Street, Edmonton AB T5J 3C5.



